Categories Earnings, Retail

Earnings preview: Investors cautious ahead of Kroger Q2 results

The Kroger Co. (KR) is scheduled to report second-quarter results before the opening bell on Thursday. The company will be depending on its robocars to lift orders partially in the second quarter and fully in the third quarter.

Analysts, on average, expect earnings of $0.37 per share for the second quarter, compared to a profit of $0.39 per share reported in the previous-year quarter. Topline is anticipated to rise 1.40% to $27.97 billion. Most analysts recommend a “hold” rating with an average price target of $30.68.

For the second quarter, investors expect the company to post a shortfall in revenue from last year, due to the lower forecast for identical supermarket sales. Growth estimates are likely to fall 5.10% for the second quarter, while it is anticipated to rise 4.50% for the next quarter.

For the recent first-quarter, the ongoing restock Kroger initiative helped post upbeat results. The results also benefited from strong cost controls and alternative revenue streams. Sales rose 3.4% and identical supermarket sales, without fuel, increased 1.4%.

For the full year 2018, the company had projected identical sales growth of 2-2.5%. Earnings were predicted to be in the range of $3.64 to $3.79 per share and adjusted earnings in the range of $2.00 to $2.15 per share.

Kroger had anticipated capital investments, excluding mergers, acquisitions, and purchases of leased facilities, to be about $3.0 billion for 2018.

Returning to second-quarter, investors are likely to focus on the company’s identical sales numbers. Traders might keen an eye on Kroger’s performance when compared with its rival retailers.

Shares of Kroger opened lower and remained grounded on Monday as investors remain concerned on the company’s future. The stock had risen by 51% for the past year and 16% so far this year.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top